KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Idexx Laboratories (IDXX) Long-Term Deferred Tax (2016 - 2018)

Idexx Laboratories has reported Long-Term Deferred Tax over the past 3 years, most recently at $9.8 million for Q1 2018.

  • Quarterly results put Long-Term Deferred Tax at $9.8 million for Q1 2018, up 67.43% from a year ago — trailing twelve months through Mar 2018 was $9.8 million (up 67.43% YoY), and the annual figure for FY2017 was $7.7 million, up 34.89%.
  • Long-Term Deferred Tax for Q1 2018 was $9.8 million at Idexx Laboratories, up from $7.7 million in the prior quarter.
  • Over the last five years, Long-Term Deferred Tax for IDXX hit a ceiling of $9.8 million in Q1 2018 and a floor of $5.7 million in Q4 2016.
  • Median Long-Term Deferred Tax over the past 3 years was $7.2 million (2017), compared with a mean of $7.3 million.
  • Biggest five-year swings in Long-Term Deferred Tax: skyrocketed 34.89% in 2017 and later soared 67.43% in 2018.
  • Idexx Laboratories' Long-Term Deferred Tax stood at $5.7 million in 2016, then surged by 34.89% to $7.7 million in 2017, then increased by 27.6% to $9.8 million in 2018.
  • The last three reported values for Long-Term Deferred Tax were $9.8 million (Q1 2018), $7.7 million (Q4 2017), and $7.9 million (Q3 2017) per Business Quant data.